HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials.

Abstract
Imipenem/cilastatin is highly effective for infections in many body sites against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria. During therapy, development of resistance is uncommon except in the case of Pseudomonas aeruginosa in which the incidence appears similar to that for other beta-lactam antibiotics. There appears to be a very low probability of cross-resistance. The clinical and laboratory adverse reactions are similar in type to those for other beta-lactam antibiotics. The frequency of colonization and superinfection during treatment with imipenem/cilastatin has been comparable to other antibiotics in comparative trials and to literature reports for other antibiotics for noncomparative trials.
AuthorsG B Calandra, F M Ricci, C Wang, K R Brown
JournalJournal of clinical pharmacology (J Clin Pharmacol) Vol. 28 Issue 2 Pg. 120-7 (Feb 1988) ISSN: 0091-2700 [Print] England
PMID3283176 (Publication Type: Journal Article, Review)
Chemical References
  • Cyclopropanes
  • Thienamycins
  • Cilastatin
  • Imipenem
Topics
  • Bacterial Infections (drug therapy, microbiology)
  • Cilastatin
  • Cyclopropanes (administration & dosage, adverse effects, therapeutic use)
  • Humans
  • Imipenem
  • Thienamycins (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: